Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) shares dropped 4.3% during trading on Tuesday. The stock traded as low as $10.5750 and last traded at $10.5750. 205 shares traded hands during trading, a decline of 98% from the average session volume of 9,080 shares. The stock had previously closed at $11.05.
Santen Pharmaceutical Price Performance
The business has a 50-day simple moving average of $11.71 and a 200 day simple moving average of $11.73.
Santen Pharmaceutical Company Profile
Santen Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company focused on ophthalmology. The company researches, develops, manufactures and commercializes prescription eye-care medicines and related products for conditions affecting vision and ocular health.
Its portfolio includes treatments for glaucoma and ocular hypertension, dry eye disease, retinal disorders, eye infections and allergies, as well as other ophthalmic conditions. Santen also conducts research in areas such as regenerative medicine and other therapies intended to address unmet needs in eye care.
Founded in Japan in 1890, Santen has expanded beyond its domestic market and serves patients and healthcare professionals across Asia, Europe and other international markets.
Featured Articles
- Five stocks we like better than Santen Pharmaceutical
- 5 Stocks Showing Why Pricing Power Matters More Than Government Money
- Rocket Lab Bounces Off Its Lows—What’s Behind the Move?
- NVIDIA Just Turned AI Safety Into a Spending Story and These 3 Stocks Benefit
- Why SpaceX Investors Should Look Past Starship’s Fiery Splashdown
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
